In a recent article for RealClearHealth, Market Institute President Charles Sauer warns that the Trump administration’s new TrumpRx initiative may deliver lower drug prices in the short run—but at the cost of future medical innovation.
Sauer explains that while the goal of lowering pharmaceutical prices is laudable, the method matters. Rather than pursuing structural reforms that increase competition and empower patients, the administration has relied on pressure campaigns to force drugmakers into compliance.
As Sauer writes in RealClearHealth, “the idea of TrumpRx is a good one. Pharmaceutical prices are high, and they should be lower. The problem is that, in setting the TrumpRx prices, President Trump is using government thug tactics instead of good public policy.”
The first company to comply was Pfizer, which agreed to both the administration’s pricing demands and a massive new domestic investment commitment. In exchange, the White House agreed to pause pharmaceutical tariffs—a deal Sauer describes as one the company “couldn’t refuse.”
Other companies soon followed, resulting in a new direct-to-consumer website offering lower-priced medications. But Sauer argues that the key question is not whether prices fall in the short term, but what happens next.
Drawing on a 2020 report from President Trump’s own Council of Economic Advisers, Sauer notes that adopting European-style price controls comes with a hidden cost: fewer new medicines and lower life expectancy. The reason is straightforward.
“Price controls undermine intellectual property rights, changing a pharmaceutical company’s incentive to invest in R&D,” Sauer writes. “Less research and development leads to fewer new drugs—and therefore lower life expectancy.”
The TrumpRx approach is based on a Most Favored Nation pricing model, which effectively imports foreign price controls into the U.S. market. Sauer argues this risks triggering a race to the bottom that weakens the incentives responsible for many of the world’s medical breakthroughs.
Instead of coercive tactics, Sauer points to patient-centered reforms that rely on competition and transparency. Allowing patients to control more of their healthcare dollars—and purchase drugs directly from manufacturers—could lower costs without undermining innovation.
“There are lots of solutions to high healthcare prices,” Sauer concludes. “However, asking CEOs to the White House to make them an offer that they can’t refuse shouldn’t be something that is even on the table.”
The challenge for policymakers is not just to win the next political fight over drug prices, but to adopt reforms that keep America the global leader in medical innovation while making care more affordable for patients.
Read more in RealClearHealth by clicking here.
0 Comments